Year None2022202120202019201820172016 05-18-2022 Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference 05-11-2022 Pliant Therapeutics to Participate in Upcoming Investor Conferences 05-09-2022 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results 05-05-2022 Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809 05-03-2022 Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis 05-02-2022 Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference 04-05-2022 Pliant Therapeutics to Participate in Needham Healthcare Conference 02-28-2022 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results 02-28-2022 Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers 02-24-2022 Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis Pagination Current page 1 Page 2 Next page next › Last page last »